指南与共识呼吸衰竭与机械通气重症综合管理与镇静镇痛

严重ARDS体外膜氧合(ECMO)治疗方案修订版:2016年2月静脉-静脉ECMO专家组的建议

Revised protocol of extracorporeal membrane oxygenation (ECMO) therapy in severe ARDS. Recommendations of the Veno-venous ECMO Expert Panel appointed in February 2016 by the national consultant on anesthesiology and intensive care.
指南 / 共识 · Anaesthesiol Intensive Ther · 2017-01-01
一句话结论静脉-静脉ECMO用于成人严重ARDS,在人工通气难以维持满意氧合时提供生命支持、等待肺功能恢复,并可能减少呼吸机相关肺损伤进展。

该修订方案由2016年2月任命的静脉-静脉ECMO专家组制定,仅针对成人严重ARDS的静脉-静脉ECMO支持。静脉-静脉ECMO不治疗急性严重病变的肺,而是让患者度过严重ARDS危重期直至肺功能恢复,除避免低氧血症致死外,还可防止人工通气导致肺损伤进一步进展。2009年甲型H1N1流感大流行以来的ECMO经验、技术进步及对呼吸机相关肺损伤病理生理认识的提高,促进了ECMO治疗结果的显著改善;与生存率提高相关的可能因素包括连接ECMO后转运患者以及较低强度的抗凝方案。方案目的是改善严重ARDS患者ECMO治疗效果、提高可能获益患者的ECMO可及性、缩短连接ECMO时间并避免对无效病例实施ECMO。

要点

  • 静脉-静脉ECMO适用于成人严重ARDS且人工通气难以提供满意氧合、以防止重要器官进一步损伤和死亡的患者。
  • 静脉-静脉ECMO不治疗急性严重病变的肺,而是让患者度过严重ARDS危重期直至肺功能恢复。
  • 除避免低氧血症致死外,静脉-静脉ECMO还可防止人工通气导致肺损伤进一步进展。
  • 可能与生存率提高相关的因素包括连接ECMO后转运患者和较低强度抗凝方案。
  • 方案目的包括缩短患者连接ECMO的时间、避免对无效病例实施ECMO。

适用人群与场景

  • 成人严重ARDS患者,人工通气难以提供满意氧合以预防重要器官进一步损伤和死亡。
  • 仅适用于静脉-静脉ECMO,不涉及静脉-动脉ECMO。

研究设计与关键结果

  • 该方案为2016年2月由全国麻醉与重症监护顾问任命的静脉-静脉ECMO专家组制定的修订方案,仅针对成人严重ARDS的静脉-静脉ECMO支持。
  • 静脉-静脉ECMO不治疗急性严重病变的肺,而是让患者度过严重ARDS危重期直至肺功能恢复。
  • 除避免低氧血症致死外,该技术还可防止人工通气导致肺损伤进一步进展。
  • 2009年甲型H1N1流感大流行以来的ECMO经验、技术进步及对呼吸机相关肺损伤病理生理认识的提高,促进了ECMO治疗结果的显著改善。
  • 与生存率提高相关的可能因素包括连接ECMO后转运患者和较低强度抗凝方案。

证据类型、等级与局限

  • 证据类型:专家组建议(指南/共识)。
  • 方案基于近期论文和作者自身经验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为该方案可为正在建立静脉-静脉ECMO项目的中心以及将患者转诊至ECMO中心的医生提供帮助和建议。
  • 方案目的包括改善严重ARDS患者ECMO治疗效果、提高可能获益患者的ECMO可及性、缩短连接ECMO时间并避免对无效病例实施ECMO。

指南或共识出处

  • 严重ARDS体外膜氧合(ECMO)治疗方案修订版:2016年2月由全国麻醉与重症监护顾问任命的静脉-静脉ECMO专家组的建议(Anaesthesiol Intensive Ther)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Extracorporeal Membrane Oxygenation (ECMO) has become well established technique of the treatment of severe acute respiratory failure (Veno-Venous ECMO) or circulatory failure (Veno-Arterial ECMO) which enables effective blood oxygenation and carbon dioxide removal for several weeks. Veno-Venous ECMO (V-V ECMO ) is a lifesaving treatment of patients in whom severe ARDS makes artificial lung ventilation unlikely to provide satisfactory blood oxygenation for preventing further vital organs damage and progression to death. The protocol below regards exclusively veno-venous ECMO treatment as a support for blood gas conditioning by means of extracorporeal circuit in adult patients with severe ARDS. V-V ECMO does not provide treatment for acutely and severely diseased lungs, but it enables patient to survive the critical phase of severe ARDS until recovery of lung function. Besides avoiding patients death from hypoxemia, this technique can also prevent further progression of the lung damage due to artificial ventilation. Recent experience of ECMO treatment since the outbreak of AH1N1 influenza pandemic in 2009, along with technical progress and advancement in understanding pathophysiology of ventilator-induced lung injury, have contributed to significant improvement of the results of ECMO treatment. Putative factors related to increased survival include patients retrieval after connecting them to ECMO, and less intensive anticoagulation protocols. The aim of presenting this revised protocol was to improve the effects of ECMO treatment in patients with severe ARDS, to enhance ECMO accessibility for patients who might possibly benefit from this treatment, to reduce time until patient's connection to ECMO, and to avoid ECMO treatment in futile cases. The authors believe that this protocol, based on recent papers and their own experience, can provide help and advice both for the centers which develop V-V ECMO program, and for doctors who will refer their patients for the treatment in an ECMO center.

来源:Anaesthesiol Intensive Ther,查看原文。版权归原作者所有。

参考来源

  1. Lango R, Szkulmowski Z, Maciejewski D, et al. Revised protocol of extracorporeal membrane oxygenation (ECMO) therapy in severe ARDS. Recommendations of the Veno-venous ECMO Expert Panel appointed in February 2016 by the national consultant on anesthesiology and intensive care. Anaesthesiol Intensive Ther. 2017. PMID: 28643320. doi:10.5603/AIT.a2017.0028

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。